These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32957974)

  • 21. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
    Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
    Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
    Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
    Isham CR; Netzel BC; Bossou AR; Milosevic D; Cradic KW; Grebe SK; Bible KC
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E936-43. PubMed ID: 24628546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
    Vasseur D; Bigot L; Beshiri K; Flórez-Arango J; Facchinetti F; Hollebecque A; Tselikas L; Aldea M; Blanc-Durand F; Gazzah A; Planchard D; Lacroix L; Pata-Merci N; Nobre C; Da Silva A; Nicotra C; Ngo-Camus M; Braye F; Nikolaev SI; Michiels S; Jules-Clement G; Olaussen KA; André F; Scoazec JY; Barlesi F; Ponce S; Soria JC; Besse B; Loriot Y; Friboulet L
    Mol Cancer; 2024 Oct; 23(1):221. PubMed ID: 39363320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Quan C; Chen Y; Wang X; Yang D; Wang Q; Huang Y; Petersen RB; Liu X; Zheng L; Li Y; Huang K
    Cancer Lett; 2020 Dec; 495():41-52. PubMed ID: 32920200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole exome sequencing and transcriptome-wide profiling identify potentially subtype-relevant genes of nasopharyngeal carcinoma.
    Liu J; Li X; Yang S; Mou J; Lu H
    Pathol Res Pract; 2020 Dec; 216(12):153244. PubMed ID: 33113455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
    Noeraparast M; Krajina K; Pichler R; Niedersüß-Beke D; Shariat SF; Grünwald V; Ahyai S; Pichler M
    Cancer Commun (Lond); 2024 Oct; 44(10):1189-1208. PubMed ID: 39161208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
    Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
    Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
    Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
    Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
    Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
    Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.
    Wu S; Yang Z; Ye R; An D; Li C; Wang Y; Wang Y; Huang Y; Liu H; Li F; He L; Sun D; Yu Y; Li Q; Huang P; Zhang M; Zhao X; Bi T; Zhuang X; Zhang L; Lu J; Sun X; Zhou F; Liu C; Yang G; Hou Y; Fan Z; Cai Z
    Oncotarget; 2016 Jan; 7(3):2629-45. PubMed ID: 26625313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.